Workflow
恩华药业(002262) - 2024 Q3 - 季度财报
NHWANHWA(SZ:002262)2024-10-25 09:46

Financial Performance - The company's revenue for Q3 2024 reached ¥1,382,065,005.72, representing a 10.07% increase compared to the same period last year[2] - Net profit attributable to shareholders for the same period was ¥391,186,854.75, up 14.74% year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥396,488,640.45, reflecting a 16.47% increase compared to the previous year[2] - Total operating revenue for the period reached ¥4,145,463,113.62, an increase of 13.4% compared to ¥3,655,985,179.26 in the previous period[13] - Net profit for the period was ¥1,016,537,195.81, up 15.1% from ¥883,414,665.34 in the same period last year[14] - The company reported a total profit of ¥1,152,398,257.88, an increase of 15.1% compared to ¥1,000,774,839.69 in the previous period[14] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥8,128,908,758.13, which is a 10.93% increase from the end of the previous year[2] - The company's equity attributable to shareholders reached ¥7,131,820,421.11, marking a 10.84% increase year-on-year[2] - Total liabilities increased to ¥1,024,692,086.38, up 11.6% from ¥918,087,703.29 in the previous period[12] - The total current liabilities increased to CNY 929,286,535.48 from CNY 814,027,830.97, indicating a growth of about 14.2%[11] Cash Flow - Cash flow from operating activities for the year-to-date was ¥911,192,693.56, showing an 11.30% increase compared to the previous year[2] - Operating cash inflow for the period reached CNY 4,548,674,103.67, an increase of 12.2% compared to CNY 4,055,730,072.31 in the previous period[16] - Net cash flow from operating activities was CNY 911,192,693.56, up from CNY 818,648,779.67, reflecting a growth of 11.0%[17] - Cash flow from financing activities showed a net outflow of CNY 265,697,908.99, worsening from a net outflow of CNY 226,555,716.90 in the previous period[17] - The net cash increase for the period was negative at CNY -560,937,755.92, contrasting with a positive increase of CNY 524,293,544.01 in the previous period[17] Investments and Expenditures - The company reported a significant increase of 34.61% in development expenditures due to increased R&D investments[5] - Research and development expenses for the period were ¥435,669,866.92, representing an increase of 13.2% from ¥384,712,055.91 in the previous period[13] - The company’s development expenditure increased to CNY 115,355,689.36 from CNY 85,696,303.65, reflecting a growth of around 34.6%[11] Shareholder Returns - The basic earnings per share for Q3 2024 was ¥0.39, an increase of 13.89% compared to the same period last year[2] - The company experienced a cash outflow of CNY 324,226,576.71 for dividend distribution, compared to CNY 204,385,678.60 in the previous period, an increase of 58.5%[17]